DaVita Inc.: An Overview of Market Performance and Future Prospects
Valued with a market capitalization of $9.4 billion, DaVita Inc. (DVA) stands as a key provider of kidney dialysis services catering to patients experiencing chronic kidney failure. Based out of Denver, Colorado, this healthcare entity not only offers various dialysis services, including outpatient, inpatient, and home-based hemodialysis treatments, but also provides clinical laboratory services.
In the financial markets, companies with a valuation of $2 billion or higher are typically categorized as “mid-cap stocks,” and DaVita fits this classification perfectly, boasting a market cap that highlights its significant size, influence, and dominance within the medical care facilities sector. The strength of DaVita lies in its expansive network of dialysis centers situated across the United States, which positions the company to effectively meet the needs of an ever-expanding population of patients diagnosed with chronic kidney disease.
Recent Developments in DaVita’s Market Performance
Despite its strong market presence, DaVita’s stock performance has shown a notable decline. The company has experienced a 27% drop from its 52-week high of $179.60 reached on January 31. Over the past three months, shares of DVA have fallen by 4.2%, significantly underperforming compared to the Nasdaq Composite’s ($NASX) impressive 17.2% gain during the same period.
Furthermore, in the longer-term perspective, DVA’s stock has decreased by 20% over the preceding 52 weeks, an underperformance when contrasted with a 27% increase in the Nasdaq index within the same timeframe. Year-to-date, shares of DVA have declined by 12.3%, whereas the Nasdaq has risen by 18%.
To substantiate its bearish trend, DaVita has been trading below its 200-day moving average since mid-February, with minor fluctuations. Additionally, it has remained under the 50-day moving average since late July.
On August 5, DaVita announced its Q2 results, leading to a steep decline in share prices of more than 9% in subsequent trading. The company reported total revenue growth of 6.1% year-over-year, reaching $3.4 billion, driven by a 4.8% increase in dialysis patient service revenues compared to the same quarter of the previous year. Its adjusted earnings per share (EPS) surged by 47.5% from the prior quarter, reaching $2.95, thanks to significant margin expansion. However, the operating cash flow took a sharp downturn, plummeting 59.4% year-over-year to $324 million, and free cash flow reiterated the trend, falling 76% to $157 million, which heightened investor apprehension.
It is worth noting that DaVita has also lagged behind its primary competitor, Fresenius Medical Care AG (FMS), which has rebounded by 26.7% over the last 52 weeks and enjoyed a 13.5% increase on a year-to-date basis.
Analysts’ Outlook
Considering DaVita’s recent struggles, analysts have adopted a cautious approach regarding its future performance. The stock carries a consensus rating of “Hold” from nine analysts covering it, with a mean price target of $153.57, indicating a potential upside of 17.1% from its current trading levels.
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data presented here are for informational purposes only. This article was initially published on Barchart.com.
